Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Silo Pharma (SILO) EBITDA (2019 - 2025)

Silo Pharma (SILO) has disclosed EBITDA for 7 consecutive years, with -$887047.0 as the latest value for Q4 2025.

  • Quarterly EBITDA rose 49.25% to -$887047.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.2 million through Dec 2025, up 3.65% year-over-year, with the annual reading at -$4.2 million for FY2025, 3.65% up from the prior year.
  • EBITDA hit -$887047.0 in Q4 2025 for Silo Pharma, up from -$1.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$436849.0 in Q2 2021 to a low of -$1.7 million in Q4 2024.
  • Historically, EBITDA has averaged -$948416.4 across 5 years, with a median of -$929729.5 in 2021.
  • Biggest YoY gain for EBITDA was 56.17% in 2021; the steepest drop was 465.48% in 2021.
  • Year by year, EBITDA stood at -$942416.0 in 2021, then crashed by 76.44% to -$1.7 million in 2022, then surged by 32.24% to -$1.1 million in 2023, then crashed by 55.15% to -$1.7 million in 2024, then soared by 49.25% to -$887047.0 in 2025.
  • Business Quant data shows EBITDA for SILO at -$887047.0 in Q4 2025, -$1.1 million in Q3 2025, and -$1.2 million in Q2 2025.